WO2025027557 - METHOD OF TREATING CUTANEOUS MELANOMA
National phase entry:
Publication Number
WO/2025/027557
Publication Date
06.02.2025
International Application No.
PCT/IB2024/057441
International Filing Date
31.07.2024
Title **
[English]
METHOD OF TREATING CUTANEOUS MELANOMA
[French]
MÉTHODE DE TRAITEMENT D'UN MÉLANOME CUTANÉ
Applicants **
IMMUNOCORE LIMITED
Inventors
ABEDIN, Shaad
DAR, Mohammed
YUAN, Yuan
MUNDY, Renee
BERMAN, David
Priority Data
63/516,914
01.08.2023
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3827 | |
| EPO | Filing, Examination, Granting | 49813 | |
| Japan | Filing, Examination, Granting | 3788 | |
| South Korea | Filing, Examination, Granting | 5386 | |
| USA | Filing, Examination, Granting | 18540 |
Total:
81,354
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present disclosure provides a method of treating cutaneous melanoma in a subject comprising administering to the subject a composition comprising a heterodimeric TCR-anti- CD3 antibody fusion molecule in a dosing regimen, wherein the dosing regimen comprises administering: (i) a first dose comprising 2 to 30 ug of the TCR-anti-CD3 antibody fusion molecule, (ii) a second dose comprising 5 to 60 µg of the TCR-anti-CD3 antibody fusion molecule, and (iii) a maintenance dose comprising 15 to 200 µg of the TCR-anti-CD3 antibody fusion molecule, wherein the maintenance dose is administered in at least three phases, wherein the first phase is administered once every 6 to 8 days, the second phase is administered once every 12 to 16 days, and the third phase is administered once every 26 to 30 days, wherein the method is a first line treatment.[French]
La présente invention concerne une méthode de traitement d'un mélanome cutané chez un sujet comprenant l'administration au sujet d'une composition comprenant une molécule de fusion d'anticorps TCR-anti-CD3 hétérodimère dans un régime posologique, le régime posologique comprenant l'administration : (i) d'une première dose comprenant de 2 à 30 ug de la molécule de fusion d'anticorps TCR-anti-CD3, (ii) d'une seconde dose comprenant de 5 à 60 µg de la molécule de fusion d'anticorps TCR-anti-CD3, et (iii) d'une dose d'entretien comprenant de 15 à 200 µg de la molécule de fusion d'anticorps TCR-anti-CD3, la dose d'entretien étant administrée dans au moins trois phases, la première phase étant administrée une fois tous les 6 à 8 jours, la deuxième phase étant administrée une fois tous les 12 à 16 jours, et la troisième phase étant administrée une fois tous les 26 à 30 jours, la méthode étant un premier traitement de ligne.